From March 18^th to 21^st, DCAT Week (annual conference of Drug, Chemical & Associated Technologies Association) took place in New York, U.S.A. More than 700 companies from over 50 countries around the world participated in the event, and APELOA PHARMACEUTICAL was among the invitees.

DCAT Week is an important business development event for companies in the field of pharmaceutical R&D, manufacturing and related industries, bringing together many world-renowned pharmaceutical companies and professionals in these fields. DCAT is a non-profit global business development association with a unique membership model that integrates innovative and generic drug manufacturers, suppliers of raw materials, development and manufacturing services, as well as other professionals working in related technologies.

During the meeting, APELOA PHARMACEUTICAL actively participated in a number of activities of DCAT and introduced its achievements in advanced manufacturing upgrade as well as R&D capacity in recent years to representatives of global pharmaceutical companies and new drug R&D organizations, demonstrating its rich legacy in CDMO business and its forward-looking deployment in terms of technology platforms and advanced production capacity. Thanks to its considerable service potential, vast experience in R&D and production, admirable customer reputation, and top-notch management systems in line with international standards, the Company was widely recognized by the participants. Through this grand event, the Company had in-depth face-to-face exchanges with numerous new and old customers, clarifying the direction for future cooperation.

In the future, APELOA PHARMACEUTICAL will adhere to the technology-driven strategy, continue to increase investment in R&D, accelerate the construction of new quality productivity, and further build core competitiveness, all in an effort to enhance the Company’s position in the global pharmaceutical industry chain, and help global customers accelerate the R&D and listing of innovative drugs.